

CLAIMS

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (original): 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.

Claim 2 (previously presented): 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate in crystalline form, having a melting point of $T_{m.p.} = 305 \pm 5^{\circ}\text{C}$ (determined by DSC; evaluation using peak-maximum; heating rate: 10°C/min).

Claim 3 (previously presented): Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate according to claim 2, the X-ray powder diagram of which includes, *inter alia*, the characteristic values $d = 5.43 \text{ \AA}$, 5.08 \AA , 4.71 \AA , 4.50 \AA and 4.43 \AA with an intensity of more than 40%.

Claim 4 (previously presented): Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate according to claim 2, characterised by a unit cell determined by X-ray powder diffractometric measurements having the following dimensions:

a = 16.332 Å,
b = 19.199 Å,
c = 11.503 Å,
 α = 95.27°,
 β = 90.13°,
 γ = 110.83° and
V = 3354.4 Å³

Claim 5 (cancelled)

Claim 6 (original): A pharmaceutical composition comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and one or more inert carriers and/or diluents.

Claim 7 (cancelled)

Claim 8 (original): A prodrug of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.

Claim 9 (cancelled)

Claim 10 (cancelled)

Application No. 10/623,971
Amendment dated May 26, 2006
Reply to Office action of March 2, 2006

Claim 11 (previously presented): 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate in crystalline form.